GRAIL, Inc. $GRAL Shares Newly Bought by Simplify Asset Management Inc.

Simplify Asset Management Inc. purchased a new position in shares of GRAIL, Inc. (NASDAQ:GRAL) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 42,969 shares of the company’s stock, valued at approximately $6,021,000. Simplify Asset Management Inc. owned about 0.10% of GRAIL at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the business. Root Financial Partners LLC acquired a new stake in GRAIL in the 3rd quarter valued at about $44,000. SBI Securities Co. Ltd. boosted its holdings in shares of GRAIL by 110.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 388 shares of the company’s stock worth $54,000 after purchasing an additional 204 shares during the last quarter. Fifth Third Bancorp boosted its holdings in shares of GRAIL by 15,733.3% during the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after purchasing an additional 472 shares during the last quarter. Allworth Financial LP purchased a new stake in shares of GRAIL in the second quarter valued at approximately $35,000. Finally, Geneos Wealth Management Inc. grew its position in shares of GRAIL by 160.0% in the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after purchasing an additional 360 shares in the last quarter.

GRAIL Stock Performance

GRAL stock opened at $157.88 on Thursday. The firm has a market cap of $7.05 billion, a PE ratio of -16.19 and a beta of 2.83. The firm’s 50 day moving average price is $109.01 and its 200-day moving average price is $78.07. GRAIL, Inc. has a one year low of $41.50 and a one year high of $166.48.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10. The firm had revenue of $44.69 million for the quarter, compared to analysts’ expectations of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. Equities research analysts predict that GRAIL, Inc. will post -10.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on GRAL. Royal Bank Of Canada initiated coverage on GRAIL in a report on Thursday, September 17th. They issued a “sector perform” rating and a $84.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Thursday, October 15th. TD Cowen boosted their price objective on GRAIL from $88.00 to $180.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Morgan Stanley upped their target price on GRAIL from $60.00 to $120.00 and gave the company an “equal weight” rating in a report on Monday, October 12th. Finally, UBS Group raised their target price on GRAIL from $105.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Five analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $119.80.

Insiders Place Their Bets

In other news, CFO Aaron Freidin sold 23,619 shares of the company’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $3,457,585.41. Following the transaction, the chief financial officer owned 225,364 shares of the company’s stock, valued at $32,991,035.96. This represents a 9.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Andrew Partridge sold 7,873 shares of the stock in a transaction on Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $1,152,528.47. Following the transaction, the insider owned 155,865 shares of the company’s stock, valued at approximately $22,817,077.35. This represents a 4.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 129,944 shares of company stock valued at $14,832,805 over the last quarter. 1.83% of the stock is owned by insiders.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.